Project Grant HT94252410621

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $216,972 to Temple University to conduct research on understanding and targeting unique vulnerabilities in small cell lung cancer (SCLC). The key products and services to be delivered under this 4-year award include: Determining the mechanistic underpinnings of the increased replication stress observed in SCLC, including the role of low levels of the LMNA nuclear structural...

This $230,010 project grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to unravel the drivers of metastasis in small cell lung cancer (SCLC) using human pluripotent stem cell-based models. The research strategy integrates stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to examine cell behavior in primary tumors and metastatic sites....

This $642,429 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Texas Southwestern Medical Center to study acquired cross-resistance in small cell lung cancer (SCLC). The researchers have generated a panel of 72 patient-derived xenograft models that faithfully mirror clinical SCLC outcomes, allowing them to investigate the molecular drivers of chemotherapy resistance. The key findings indicate that...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding to Purdue University to identify selective small molecule inhibitors of the phospholipase C gamma (PLCG1 and PLCG2) enzymes. The $572,254 award, active from February 1, 2025 to January 31, 2028, will support the development and optimization of high-throughput screening assays using novel fluorescent substrates to screen 200,000 compounds against the PLCG enzymes. Confirmed...

This $631,156 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to uncover mechanisms driving lineage plasticity in lung cancer. The award recipient, the Icahn School of Medicine at Mount Sinai, will systematically investigate how genetic and epigenetic changes, particularly in the Notch signaling pathway and lineage-determining transcription factors, contribute to the transition from lung adenocarcinoma to the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the University of Southern California to develop a monoclonal antibody targeting a specific post-translational modification (isoaspartylation) of the ELAVL4 protein, which is expressed on the surface of small cell lung cancer (SCLC) tumors. The key objectives are to: 1) Generate a mouse monoclonal antibody specifically targeting isoaspartylated ELAVL4, and 2) Test the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,506,651.00 to Virginia Commonwealth University to evaluate a new agent, PEPDG278D, for overcoming drug resistance in non-small cell lung cancer (NSCLC). The key objectives are to: Assess PEPDG278D for inhibiting oncogenic signaling and anti-tumor activity in NSCLC cells and tumors expressing wild-type EGFR, and compare it to the approved EGFR-directed monoclonal antibody necitumumab....

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $191,675 is funding research to investigate the role of Jumonji demethylases as druggable targets for treating small cell lung cancer (SCLC), including in SCLC that has developed resistance to standard chemotherapy. The research will explore a three-pronged therapeutic approach: using Jumonji inhibitors as first-line therapy, treating etoposide-resistant SCLC with Jumonji...

The federal Project Grant award of $424,836 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate drug-tolerant persister cells in small cell lung cancer (SCLC). The key objectives are to: 1) Characterize the molecular profile and trajectory of drug-tolerant persister cells in SCLC models and patient samples following standard platinum-based chemotherapy; 2) Evaluate the ability of a recently-approved bispecific T-cell engager against delta-like...